Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026GlobeNewsWire · Oct 13, 2026
Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)Defense World · Oct 8, 2026
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for EndometriosisGlobeNewsWire · Sep 24, 2026
Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head ContrastDefense World · Sep 21, 2026
Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN)Defense World · Sep 21, 2026
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 16, 2026Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.19 | -$0.18 | Beat |
| May 7, 2026 | -$0.20 | -$0.19 | Beat |
| Mar 24, 2026 | -$0.16 | -$0.23 | Miss |
| Nov 12, 2025 | -$0.19 | -$0.20 | Miss |
| Aug 12, 2025 | -$0.19 | -$0.24 | Miss |
| May 13, 2025 | -$0.23 | -$0.21 | Beat |